Volume 13, Number 9—September 2007
Dispatch
Parenteral Transmission of the Novel Human Parvovirus PARV4
Peter Simmonds*
, Ashleigh Manning*, Rachel Kenneil*, Frances W. Carnie†, and Jeanne E. Bell†
, Ashleigh Manning*, Rachel Kenneil*, Frances W. Carnie†, and Jeanne E. Bell†Table 1
Detection of parvovirus B19 and PARV4 in study groups*
| Participant category (no.) | M/F | Age at death, y (range)† | Year of death (range)† | Mean CD4/μL (range)† | AIDS? | B19 positive, no. (%) | PARV4 positive, no. (%) |
|---|---|---|---|---|---|---|---|
| HIV+ IDU, AIDS‡ (13) | 10/3 | 35 (2–48) | 1995 (1991–1998) | 44 (1–137) | Y | 6 (46) | 11 (85) |
| HIV+ IDU, pre-AIDS‡ (11) | 7/4 | 33 (29–40) | 1996 (1992–1998) | 268 (167–496) | N | 6 (55) | 6 (55) |
| HIV+ MSM (13) | 13/0 | 39 (28–49) | 1993 (1990–1996) | 25 (1–160) | Y | 7 (54) | 0 |
| HIV– IDU (12) | 10/2 | 35 (24–49) | 1999 (1992–2005) | ND | NA | 8 (67) | 1 (8) |
| Hemophilia (2) | 2/0 | 22, 26 | 1994, 1995 | 0 | Y | 0 | 1 (50) |
| Low-risk control§ (8) | 3/5 | 54 (28–89) | All 2005 | ND | NA | 8 (100) | 0 |
*IDU, injection drug user; M, male; F, female; Y, yes; N, no; MSM, men who had sex with men; ND, not done; NA, not applicable.
†Values are means (ranges) or individual values for those with hemophilia.
‡These study groups overlap with the previously analyzed HIV-positive group (8), restricted to those in whom parenteral risk factors for infection have been identified.
§Previously described in (8).
